- Premium Stock Alerts
- Posts
- Pre-Bell Profit Plays
Pre-Bell Profit Plays
Noor Saba
March 14, 2024
Pre-Bell Profit Plays
Don’t want emails from us anymore? Click here to unsubscribe
Hello Part-time Trader…👋
Premium Stock Alerts is here with your pre-market cheat sheet. 🚀 Unusual movers, 🎞️ market snapshot, and 💥 crucial news – we've got it all!
Happening Today
✓ 08:30 – Core Retail Sales (MoM) (Feb)
✓ 08:30 – Initial Jobless Claims
✓ 08:30 – PPI (MoM) (Feb)
✓ 08:30 – Retail Sales (MoM) (Feb)
Daily Quote
Trade not on the whispers of the crowd, but on the whispers of your informed conviction.
One brand-new weekly profit strategy is taking the gains from these AI stocks to an entirely new level this year.
Research shows that one stock (C3.AI) could have produced a top gain of 2,614%... which would have been enough to turn a mere $1,000 investment into $23,069 within just 10 days!
The next opportunity to take advantage of this new strategy will be next Monday.
Watch this presentation before then!
Sponsored
PREMARKET SNAPSHOT 📈
Stock futures mixed: S&P 500 dips slightly, Dow edges up, and Nasdaq leads with a steeper decline.
S&P500 $5165.31 ⬇️ -0.19% | Dow $39043.32 ⬆️ 0.097% | NASDAQ $18068.467 ⬇️ -0.8269% |
SECTOR SNAPSHOT ✨
Energy (+1.52%) leads the pack today, followed by Materials (+0.91%) and Utilities (+0.66%). Information Technology (-1.08%) and Consumer Discretionary (-0.11%) lag behind.
NAME | PRICE | %CHANGE |
|---|---|---|
Consumer Discretionary | 1,458.03 | -0.11% 🔴 |
Consumer Staples | 806.88 | +0.13% 🟢 |
Energy | 684.35 | +1.52% 🟢 |
Financials | 682.18 | +0.57% 🟢 |
Health Care | 1,703.60 | -0.41% 🔴 |
Industrials | 1,034.20 | +0.24% 🟢 |
Materials | 572.99 | +0.91% 🟢 |
Real Estate | 248.03 | -0.60% 🔴 |
Information Technology | 3,813.85 | -1.08% 🔴 |
Communication Services | 275.11 | +0.16% 🟢 |
Utilities | 321.94 | +0.66% 🟢 |
Unusual Volume
📈 Kintara Therapeutics Inc (KTRA) jumped 46.05% to $0.12 on a whopping 143.83 million shares traded.
📈 Investors went wild, sending Li-Cycle Holdings Corp (LICY) stock soaring 36.26% to $0.80 on a massive volume of 75.47 million shares after the company announced $75 million strategic investment from Glencore.
📈 Abnormal activity shook BYND Cannasoft Enterprises Inc (BCAN), pushing it down -11.69% to $0.03 on a whopping 68.14 million shares traded. This decrease followed pricing of $7.0 million underwritten public offering..
📈 NuCana plc ADR (NCNA) stock recently closed 9.21% upper at $0.42 on substantial volume of 63.84 million shares.
📈 WiSA Technologies Inc (WISA) increase by 9.97% in a single trading session, with abnormally high trading volume of 59.7 million shares.
Pre Market Gainers | Pre Market Change | Pre Market Volume |
|---|---|---|
PRST | +42.20% | 3.11M |
SOUN | +9.83% | 1.38M |
CCTG | +33.13% | 1.20M |
PIXY | +39.38% | 965.08K |
BBAI | +12.80% | 686.28K |
SPRO | +16.87% | 598.50K |
JAGX | +8.79% | 517.10K |
ZCAR | +5.00% | 476.42K |
AUUD | +13.45% | 357.84K |
PATH | +7.45% | 227.60K |
With so many AI stocks out there, finding those worthy of investment can be confusing (and time consuming). Here's one that's definitely worth a look.
Get this AI Stock Ticker Now!
Sponsored
Important FDA
Recently Announced
Mirum Pharmaceuticals Inc. (MIRM) received FDA approval for expanded use of LIVMARLI in progressive familial intrahepatic cholestasis, specifically for treating cholestatic pruritus in patients aged five years and older on March 13, 2024.
Viatris Inc.'s (VTRS) GA Depot 40 mg faced FDA's decline for approval in Relapsing Forms of Multiple Sclerosis on March 11, 2024.
EYENOVIA, INC.'s (EYEN) APP13007 gained FDA approval for treating inflammation and pain following ocular surgery on March 5, 2024.
Announcing Today
On March 14, 2024, Bristol-Myers Squibb Co. (BMY) anticipates FDA's verdict on expanding Breyanzi's usage for relapsed or refractory chronic lymphocytic leukemia treatment.
Geron Corporation's (GERN) Imetelstat undergoes FDA panel review for treating transfusion-dependent anemia in lower risk myelodysplastic syndromes patients as of March 14, 2024.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) awaits FDA's decision regarding Resmetirom for adult NASH patients with liver fibrosis treatment, as of March 14, 2024.
Upcoming this Week
This week, Johnson & Johnson (JNJ) and Legend Biotech Corporation (LEGN) stand on the brink as they await FDA panel deliberation on extending CARVYKTI's application to treat relapsed or refractory multiple myeloma in adults who have undergone prior therapy lines, a decision expected by March 15, 2024.
Meanwhile, OptiNose Inc. (OPTN) braces for the FDA's decision regarding XHANCE's potential expansion in treating chronic rhinosinusitis, with the outcome expected to be revealed by March 16, 2024.
Happy investing,
Maeve Grace
Editor In Cheif
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Reply